Quanterix and Janssen will work together to advance the detection of blood-based Alzheimer’s disease. Credit: Tatiana from Pixabay.

Quanterix has entered a licence agreement with Johnson & Johnson (J&J) company Janssen Sciences Ireland UC (Janssen) to advance the detection of blood-based Alzheimer’s disease.

Under the deal, Quanterix will gain global, non-exclusive rights to the p-Tau 217 antibodies and assay designs of J&J for potential utilisation in clinical research and diagnostic products.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company will also receive a non-exclusive licence from Janssen for J&J-developed technology for producing Simoa p-Tau 217 research-use-only assay kits to distribute globally.

Quanterix will also introduce a laboratory-developed test based on the J&J p-Tau 217 antibodies and assay. It will be offered via Accelerator under the Lucent Diagnostics brand.

These advancements enable Quanterix to pave the way for the first widely accessible immunoassay-based p-Tau 217 test for clinicians and researchers.

See Also:

Quanterix CEO Masoud Toloue said: “This collaboration demonstrates the scientific advances that are possible when Simoa’s ultra-sensitive detection is combined with clinically validated antibodies and critical reagents.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Providing access to high-performing blood-based p-Tau 217 assays are an important step as we work with several partners to build the global infrastructure for non-invasive testing of Alzheimer’s disease.”

Blood-based biomarker tests with high sensitivity and specificity have the potential to enhance early Alzheimer’s disease diagnosis, increasing treatment accessibility for millions of individuals.

Currently, Alzheimer’s diagnosis depends on positron emission tomography or cerebrospinal fluid biomarkers obtained through lumbar puncture.